Urogen Pharma (URGN) Reaches New 52-Week Low at $34.54

Urogen Pharma Ltd (NASDAQ:URGN)’s share price reached a new 52-week low on Wednesday . The company traded as low as $34.54 and last traded at $34.86, with a volume of 158419 shares traded. The stock had previously closed at $36.49.

URGN has been the topic of a number of recent analyst reports. Raymond James set a $57.00 price target on shares of Urogen Pharma and gave the stock a “buy” rating in a research note on Friday, March 1st. Oppenheimer set a $70.00 price objective on shares of Urogen Pharma and gave the company a “buy” rating in a research note on Thursday, February 28th. Zacks Investment Research raised shares of Urogen Pharma from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a research note on Saturday, May 11th. HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Urogen Pharma in a research note on Friday, March 1st. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $63.00 price objective on shares of Urogen Pharma in a research note on Tuesday, March 5th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Urogen Pharma currently has a consensus rating of “Buy” and an average price target of $59.50.

The firm has a market cap of $466.40 million, a PE ratio of -7.01 and a beta of 1.33.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Thursday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.12) by $0.01. Urogen Pharma had a negative net margin of 4,296.08% and a negative return on equity of 61.24%. As a group, equities analysts forecast that Urogen Pharma Ltd will post -5.41 earnings per share for the current fiscal year.

In other news, insider Mark Schoenberg sold 1,991 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $37.30, for a total transaction of $74,264.30. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 10.50% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC grew its position in Urogen Pharma by 5.8% in the first quarter. FMR LLC now owns 588,203 shares of the company’s stock valued at $21,728,000 after acquiring an additional 32,200 shares in the last quarter. Wildcat Capital Management LLC grew its position in Urogen Pharma by 27.2% in the first quarter. Wildcat Capital Management LLC now owns 779,003 shares of the company’s stock valued at $28,776,000 after acquiring an additional 166,509 shares in the last quarter. Morgan Stanley grew its position in Urogen Pharma by 65.4% in the first quarter. Morgan Stanley now owns 24,923 shares of the company’s stock valued at $920,000 after acquiring an additional 9,856 shares in the last quarter. Man Group plc grew its position in Urogen Pharma by 49.5% in the first quarter. Man Group plc now owns 178,996 shares of the company’s stock valued at $6,612,000 after acquiring an additional 59,260 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Urogen Pharma by 267.4% in the first quarter. Goldman Sachs Group Inc. now owns 59,445 shares of the company’s stock valued at $2,196,000 after acquiring an additional 43,266 shares in the last quarter. 97.86% of the stock is owned by hedge funds and other institutional investors.

WARNING: This article was posted by Rockland Register and is the sole property of of Rockland Register. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://rocklandregister.com/2019/05/31/urogen-pharma-urgn-reaches-new-52-week-low-at-34-54.html.

Urogen Pharma Company Profile (NASDAQ:URGN)

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Read More: Technical Analysis of Stocks and What It Means

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.